Bavarian Nordic faced a challenging close to 2024, with Q3 revenue falling 26% compared to the same interval in 2023.

Bavarian Nordic A/S (($BVNRY)) has held its Q1 earnings call. Read on for the main highlights of the call. Bavarian Nordic’s recent earnings call ...

Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three ...

The earnings before interest, tax, depreciation and amortization margin rose to 31% from 3%, and Bavarian Nordic maintained guidance for a full-year EBITDA margin of 26%-30% with revenue still seen at ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Bavarian Nordic’s Vimkunya (recombinant, adsorbed ...

The options are for the freeze-dried version of Bavarian Nordic’s Jynneos, a formulation that allows easier stockpiling.

Bavarian Nordic reported a robust start to 2025 with a 62% year-over-year increase in revenue for the first quarter, reaching 1,347 million Danish krona. Despite the absence of specific earnings f ...

European stock markets saw gains. Germany's DAX reached a record high. Investors felt relieved by signs of a possible ease in ...

Exercised options total USD 143.6 million <li /> Secures manufacturing and supply of freeze-dried JYNNEOS® to the U.S. in 20 ...

Copenhagen, Denmark Saturday, May 3, 2025, 12:00 Hrs [IST] ...

Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2025. Revenue for the first three ...